U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Banjaras Inc - 589115 - 03/24/2019
  1. Warning Letters

CLOSEOUT LETTER

Banjaras Inc MARCS-CMS 589115 —

Product:
Food & Beverages
Recipient:
Recipient Name
Ms. Sumit Kaur
Recipient Title
President
Banjaras Inc

2707 Gallion Dr.
Sugar Land, TX 77479-1979
United States

Issuing Office:
Division of Southwest Imports

United States

Dear Ms. Kaur,

The Food and Drug Administration has completed evaluation of your firm’s corrective actions in response to our Warning Letter Ref: CMS 589115 dated September 25, 2019. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
Rosa Linda Santos
Compliance Officer

Back to Top